The market for adeno-associated virus (AAV) gene therapies is expanding toward treatments for common diseases like Alzheimer’s and cardiovascular conditions. This growth demands scalable, consistent manufacturing processes to overcome variability and reduce costs. Industry experts advocate partnering with contract development and manufacturing organizations (CDMOs) to leverage optimized platforms that improve quality, yield, and commercial viability. These advances aim to meet regulatory and supply challenges as the sector moves from rare diseases to broader patient populations.